Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Argatroban Plus R-tPA for Acute Posterior Circulation Infarction (AR-PCI): a Prospective, Random, Blinded Assessment of Outcome and Open Label Multi-center Study

NCT03506009 is registered in ClinicalTrials.gov with Hui-Sheng Chen as lead sponsor.

NCT NCT03506009
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03506009 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Argatroban Plus R-tPA for Acute Posterior Circulation Infarction (AR-PCI): a Prospective, Random, Blinded Assessment of Outcome and Open Label Multi-center Study
Lead sponsor
Hui-Sheng Chen
Phase
Phase 4
Overall status
Terminated
Start date
July 11, 2018
Completion date
November 13, 2018
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

argatroban, rt-pa